Abstract
Background/Aims The Cancer Survival Query System (CSQS) is a second generation prototype cancer prognostic tool developed by the National Cancer Institute (NCI). It was designed for physicians to use so they could better understand and communicate with prostate and colorectal cancer patients valid estimates of their cancer survival within the context of all causes of death. The aim of this study was to assess the market readiness and enhance the likelihood of large-scale adoption of CSQS.
Methods We conducted a small-scale implementation study of the CSQS prognostic tool in two, purposively selected, diverse healthcare delivery systems (Kaiser Permanente Colorado and Penrose Cancer Center) in the specialty care context (oncology, urology, surgery) using a mixed method design. Additionally, two private urology practices affiliated with Penrose were incorporated into the study. Implementation strategies included identifying site champions, champions working with study staff to conduct a roll-out meeting for their department, and champions sending CSQS reminder emails drafted by study staff. Data collection consisted of automated usage tracking, follow-up champion interviews, and field notes from roll-out meetings and champion interviews.
Results 96 providers attended the roll-out meetings with study staff across the seven departments. 110 providers were reached through the follow-up email sent by champions. 158 providers had login information created for access to CSQS, with 16 individual providers entering 52 different case scenarios (n=26 prostate, n=16 colorectal). KP Urology and Penrose GI departments utilized CSQS the most. Seven of the nine site champions completed the key informant interview. Ten themes were identified from qualitative analysis, including champion recommendation of CSQS to colleagues, providers using CSQS without patients in the room, and discussion of CSQS results by nurses was out of their scope of work.
Conclusions Usage was consistent between the data pulls over five months. All champions agreed a patient-facing version would benefit patient-provider communication. Next steps include usability testing of CSQS with prostate and colorectal cancer survivors. Data collected from the one-on-one testing will be used to inform NCI on a patient-facing version of CSQS.
